Neon Therapeutics Inc (NASDAQ:NTGN) has earned an average recommendation of “Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $19.33.

NTGN has been the topic of a number of analyst reports. Zacks Investment Research cut Neon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. Berenberg Bank initiated coverage on Neon Therapeutics in a research report on Wednesday, March 27th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, ValuEngine cut Neon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.

A number of institutional investors and hedge funds have recently modified their holdings of NTGN. Harel Insurance Investments & Financial Services Ltd. raised its stake in Neon Therapeutics by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after purchasing an additional 5,000 shares during the period. Bank of New York Mellon Corp increased its stake in Neon Therapeutics by 17.6% in the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock worth $98,000 after acquiring an additional 2,905 shares during the last quarter. Bank of America Corp DE increased its stake in Neon Therapeutics by 42.7% in the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock worth $109,000 after acquiring an additional 6,493 shares during the last quarter. Geode Capital Management LLC increased its stake in Neon Therapeutics by 127.0% in the 4th quarter. Geode Capital Management LLC now owns 60,309 shares of the company’s stock worth $303,000 after acquiring an additional 33,741 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Neon Therapeutics by 68.9% in the 4th quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock worth $446,000 after acquiring an additional 36,170 shares during the last quarter. 69.96% of the stock is currently owned by institutional investors.

Shares of NTGN stock traded down $0.14 during trading hours on Monday, reaching $6.08. 157 shares of the company traded hands, compared to its average volume of 163,149. Neon Therapeutics has a 12-month low of $4.20 and a 12-month high of $16.23. The stock has a market cap of $176.22 million and a P/E ratio of -1.08.

Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.11). As a group, equities analysts forecast that Neon Therapeutics will post -2.74 earnings per share for the current year.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: What is the Coverage Ratio?

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.